STOCKHOLDERS' EQUITY Stock Issuances When the Company completes a business combination or asset acquisition, which are further described in Note 18, the Company may issue shares of the Company's common stock. Stock issuances in relation to acquisitions during the years ended December 31, 2022, 2021 and 2020 were as follows: | | | | | | | | | | | | | | | | | | | | | (In millions) | | Period of Acquisition | | Shares Issued | | Fair Value of Shares Issued | OmicEra | | May 2022 | | 0.3 | | $ | 14.8 | | PreventionGenetics | | December 2021 | | 1.1 | | 84.2 | | Ashion | | April 2021 | | 0.1 | | 16.2 | | Thrive | | January 2021 | | 9.3 | | 1,190.0 | | Targeted Digital Sequencing (“TARDIS”) license | | January 2021 | | 0.2 | | 27.3 | | Paradigm Diagnostics, Inc. (“Paradigm”) and Viomics, Inc. (“Viomics”) | | March 2020 | | 0.4 | | 28.8 | |
Registered Direct Offering In October 2020, the Company entered into securities purchase agreements with a limited number of institutional investors for the registered direct offering of 8.6 million shares of common stock at a price of $101.00 per share. The Company received, in the aggregate, approximately $861.7 million of net proceeds from the offering, after deducting $7.5 million for the offering expenses and other stock issuance costs paid by the Company. Changes in Accumulated Other Comprehensive Loss The amount recognized in AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows: | | | | | | | | | | | | | | | | | | | | | (In thousands) | | Cumulative Translation Adjustment | | Unrealized Gain (Loss) on Securities | | Accumulated Other Comprehensive Income (Loss) | Balance at January 1, 2020 | | $ | (25) | | | $ | (75) | | | $ | (100) | | Other comprehensive income before reclassifications | | — | | | 771 | | | 771 | | Amounts reclassified from accumulated other comprehensive loss | | 25 | | | — | | | 25 | | Net current period change in accumulated other comprehensive loss | | 25 | | | 771 | | | 796 | | Income tax expense related to items of other comprehensive loss | | — | | | (170) | | | (170) | | Balance at December 31, 2020 | | $ | — | | | $ | 526 | | | $ | 526 | | Other comprehensive income (loss) before reclassifications | | 23 | | | (1,648) | | | (1,625) | | Amounts reclassified from accumulated other comprehensive loss | | — | | | (514) | | | (514) | | Net current period change in accumulated other comprehensive loss | | 23 | | | (2,162) | | | (2,139) | | Income tax benefit related to items of other comprehensive loss | | — | | | 170 | | | 170 | | Balance at December 31, 2021 | | $ | 23 | | | $ | (1,466) | | | $ | (1,443) | | Other comprehensive income (loss) before reclassifications | | 30 | | | (4,049) | | | (4,019) | | Amounts reclassified from accumulated other comprehensive loss | | — | | | 226 | | | 226 | | Net current period change in accumulated other comprehensive loss | | 30 | | | (3,823) | | | (3,793) | | Balance at December 31, 2022 | | $ | 53 | | | $ | (5,289) | | | $ | (5,236) | |
_________________________________ (1)There was no tax impact from the amounts recognized in AOCI for the year ended December 31, 2022. Amounts reclassified from AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | Details about AOCI Components (In thousands) | | Affected Line Item in the Statements of Operations | | 2022 | | 2021 | | 2020 | Change in value of available-for-sale investments | | | | | | | | | Sales and maturities of available-for-sale investments | | Investment income | | $ | 226 | | | $ | (514) | | | $ | — | | Foreign currency adjustment | | General and administrative | | — | | | — | | | 25 | | Total reclassifications | | | | $ | 226 | | | $ | (514) | | | $ | 25 | |
|